Groowe BETA / Newsroom

⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

武田制药Zasocitinib（泽索昔替尼）在3期银屑病研究中显示出全身一致的高皮损清除率，包括难治及高影响部位

businesswire.com July 28, 2026 at 3:54 PM ET

TAK Takeda's drug Zasocitinib showed consistent high skin clearance rates in a Phase 3 psoriasis study, including in difficult-to-treat and high-impact areas, indicating strong efficacy.